These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10192757)

  • 1. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
    Buter H; Navis GY; Woittiez AJ; de Zeeuw D; de Jong PE
    Eur J Clin Pharmacol; 1999 Feb; 54(12):953-8. PubMed ID: 10192757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of candesartan.
    Gleiter CH; Mörike KE
    Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
    de Zeeuw D; Remuzzi G; Kirch W
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
    Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E
    Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis.
    Meineke I; Feltkamp H; Högemann A; Gundert-Remy U
    Eur J Clin Pharmacol; 1997; 53(3-4):221-8. PubMed ID: 9476035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE; Jarvis B
    Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
    Belz GG; Butzer R; Kober S; Mutschler E
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
    J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.
    Pfister M; Schaedeli F; Frey FJ; Uehlinger DE
    Br J Clin Pharmacol; 1999 Jun; 47(6):645-51. PubMed ID: 10383542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K; Naka T; Chatani F; Yoshimura Y
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
    Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
    Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
    Pietruck F; Kiel G; Birkel M; Stahlheber-Dilg B; Philipp T
    Biopharm Drug Dispos; 2005 May; 26(4):135-41. PubMed ID: 15768377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
    Cervenka L; Wang CT; Navar LG
    Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.